Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
FPMI > SEC Filings for FPMI > Form 8-K on 1-Jul-2014All Recent SEC Filings

Show all filings for FLUOROPHARMA MEDICAL, INC.

Form 8-K for FLUOROPHARMA MEDICAL, INC.


1-Jul-2014

Entry into a Material Definitive Agreement, Financial Statements and E


Item 1.01. Entry Into a Definitive Material Agreement.

On June 26, 2014, FluoroPharma Medical, Inc. (the "Company," "we" or "us") and The General Hospital Corporation, d/b/a Massachusetts General Hospital ("MGH") entered into two license agreements (the "Agreements"), which Agreements replace the single license agreement between the Company and MGH dated April 27, 2009, as amended by letter dated June 21, 2011 and agreement dated October 31, 2011 (the "Original Agreement"). The Agreements provide exclusive licenses for our two lead product candidates, BFPET and CardioPET, two of the three cardiac imaging technologies covered by the Original Agreement. The Company and MGH are in discussions regarding the exclusive license to VasoPET, the third product candidate covered by the Original Agreement, our rights to which ceased upon the termination of the Original Agreement contemporaneously with the execution of the new Agreements.

The Agreements were entered into primarily for the purpose of separating the Company's rights and obligations with respect to its different product development programs.

Each of the Agreements requires us to pay MGH an initial license fee of $175,000 and annual license maintenance fees aggregating $250,000. The Agreements require us to meet certain obligations, including, but not limited to, meeting certain development milestones relating to clinical trials and filings with the United States Food and Drug Administration. MGH has the right to cancel or make non-exclusive certain licenses on certain patents should we fail to meet stipulated obligations and milestones. Additionally, upon commercialization, we are required to make specified milestone payments and royalties on commercial sales.

Copies of the Agreements are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and the description thereof contained in this Current Report on Form 8-K is qualified in its entirety be reference to such exhibits.



Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

Exhibit No.                         Description

              License Agreement (Number A220395) dated as of June 1,
   10.1*      2014 between the Registrant and The General Hospital
              Corporation, d/b/a Massachusetts General Hospital
              License Agreement (Number A220396) dated as of June 1,
   10.2*      2014 between the Registrant and The General Hospital
              Corporation, d/b/a Massachusetts General Hospital

*Confidential treatment has been requested with respect to portions of this exhibit.


  Add FPMI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for FPMI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.